Do analysts prefer BVXP or STX?

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer STX or VLG?

Shield Therapeutics presently has a consensus target price of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Venture Life Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, STX or ORPH?

Open Orphan has lower revenue, but higher earnings than Shield Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shield Therapeutics £58.63M 1.09 -£36.28M -£1.00 N/A Open Orphan £34.71M 0.00 N/A N/A N/A

Shield Therapeutics (STX) Competitors

GBX 5.95 -0.10 (-1.60%)

As of 12:18 PM Eastern

Compare

STX vs. BVXP, VLG, ORPH, EAH, and MRK

Should you buy Shield Therapeutics stock or one of its competitors? Shield Therapeutics's main competitors and comparable companies include Bioventix (BVXP), Venture Life Group (VLG), Open Orphan (ORPH), ECO Animal Health Group (EAH), and Marks Electrical Group (MRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Shield Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Bioventix has a net margin of 59.30% compared to Shield Therapeutics' net margin of -17.76%. Bioventix's return on equity of 65.83% beat Shield Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Shield Therapeutics	-17.76%	64.57%	-47.85%

In the previous week, Bioventix had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Shield Therapeutics. Bioventix's average media sentiment score of 0.75 beat Shield Therapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventix	Positive
Shield Therapeutics	Neutral

Bioventix has a beta of 0.555, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, suggesting that its stock price is 77% more volatile than the broader market.

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bioventix has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.89	£8.12M	£140.52	11.78
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Bioventix beats Shield Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Shield Therapeutics compare to Venture Life Group?

Shield Therapeutics (LON:STX) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Shield Therapeutics has a beta of 1.768, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, suggesting that its share price is 77% less volatile than the broader market.

Venture Life Group has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A
Venture Life Group	£35.17M	2.37	£747.21K	£4.37	15.88

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 21.9% of Venture Life Group shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Comparatively, 7.5% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Venture Life Group had 9 more articles in the media than Shield Therapeutics. MarketBeat recorded 9 mentions for Venture Life Group and 0 mentions for Shield Therapeutics. Venture Life Group's average media sentiment score of 1.30 beat Shield Therapeutics' score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
Venture Life Group	Positive

Venture Life Group has a net margin of 17.42% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Venture Life Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
Venture Life Group	17.42%	7.82%	1.56%

Shield Therapeutics presently has a consensus target price of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Venture Life Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Venture Life Group beats Shield Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Shield Therapeutics compare to Open Orphan?

Shield Therapeutics (LON:STX) and Open Orphan (LON:ORPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company	Overall Sentiment
Shield Therapeutics	Neutral
Open Orphan	Neutral

Open Orphan has a net margin of 0.00% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Open Orphan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
Open Orphan	N/A	N/A	N/A

Shield Therapeutics presently has a consensus target price of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shield Therapeutics is more favorable than Open Orphan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Open Orphan	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Open Orphan has lower revenue, but higher earnings than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A
Open Orphan	£34.71M	0.00	N/A	N/A	N/A

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Shield Therapeutics beats Open Orphan on 8 of the 10 factors compared between the two stocks.

How does Shield Therapeutics compare to ECO Animal Health Group?

ECO Animal Health Group (LON:EAH) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

In the previous week, ECO Animal Health Group had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 1 mentions for ECO Animal Health Group and 0 mentions for Shield Therapeutics. ECO Animal Health Group's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company	Overall Sentiment
ECO Animal Health Group	Neutral
Shield Therapeutics	Neutral

ECO Animal Health Group has a net margin of 2.50% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat ECO Animal Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ECO Animal Health Group	2.50%	2.55%	2.14%
Shield Therapeutics	-17.76%	64.57%	-47.85%

ECO Animal Health Group has a beta of 0.701, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, suggesting that its share price is 77% more volatile than the broader market.

40.6% of ECO Animal Health Group shares are held by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are held by institutional investors. 11.3% of ECO Animal Health Group shares are held by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ECO Animal Health Group has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ECO Animal Health Group	£87.53M	0.75	£1.05M	£3.15	31.17
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A

ECO Animal Health Group currently has a consensus price target of GBX 160, indicating a potential upside of 62.95%. Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 151.97%. Given Shield Therapeutics' higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than ECO Animal Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ECO Animal Health Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

ECO Animal Health Group beats Shield Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to Marks Electrical Group?

Shield Therapeutics (LON:STX) and Marks Electrical Group (LON:MRK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Marks Electrical Group's average media sentiment score of 1.12 beat Shield Therapeutics' score of 0.00 indicating that Marks Electrical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
Marks Electrical Group	Positive

Shield Therapeutics has a beta of 1.768, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Marks Electrical Group has a beta of 0.577, suggesting that its share price is 42% less volatile than the broader market.

Marks Electrical Group has a net margin of -0.39% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Marks Electrical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
Marks Electrical Group	-0.39%	-4.18%	0.91%

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 151.97%. Marks Electrical Group has a consensus price target of GBX 52.50, suggesting a potential upside of 5.00%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Shield Therapeutics is more favorable than Marks Electrical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Marks Electrical Group	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Marks Electrical Group has higher revenue and earnings than Shield Therapeutics. Marks Electrical Group is trading at a lower price-to-earnings ratio than Shield Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A
Marks Electrical Group	£107.93M	0.48	£426.93K	-£0.40	N/A

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Marks Electrical Group shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Comparatively, 75.4% of Marks Electrical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Marks Electrical Group beats Shield Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STX vs. The Competition

Export

Metric	Shield Therapeutics	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£63.69M	£12.21B	£7.10B	£2.80B
Dividend Yield	N/A	2.63%	2.53%	6.18%
P/E Ratio	-5.95	797.15	274.33	366.17
Price / Sales	1.09	751.67	601.06	89,425.29
Price / Cash	6.36	81.79	77.38	27.89
Price / Book	108.78	10.47	10.92	6.83
Net Income	-£36.28M	£2.83B	£3.50B	£5.89B
7 Day Performance	15.59%	-1.66%	-2.11%	-0.75%
1 Month Performance	2.64%	-5.78%	-6.34%	16.84%
1 Year Performance	-24.65%	-3.81%	8.81%	16.40%

Shield Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STX Shield Therapeutics	1.1467 of 5 stars	GBX 5.95 -1.6%	GBX 15 +152.0%	-22.6%	£63.69M	£58.63M	N/A	40,000
BVXP Bioventix	N/A	GBX 1,600 +3.2%	N/A	-31.7%	£83.60M	£12.54M	11.39	12
VLG Venture Life Group	N/A	GBX 67.40 -1.2%	N/A	+22.5%	£80.91M	£35.17M	15.42	165	News Coverage Earnings Report Insider Trade
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
EAH ECO Animal Health Group	3.2029 of 5 stars	GBX 98.08 +2.2%	GBX 160 +63.1%	+6.6%	£65.45M	£87.53M	31.14	234

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:STX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shield Therapeutics (STX) Competitors

STX vs. BVXP, VLG, ORPH, EAH, and MRK

How does Shield Therapeutics compare to Bioventix?

Summary

How does Shield Therapeutics compare to Venture Life Group?

Summary

How does Shield Therapeutics compare to Open Orphan?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Summary

How does Shield Therapeutics compare to Marks Electrical Group?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shield Therapeutics (STX) Competitors

STX vs. BVXP, VLG, ORPH, EAH, and MRK

How does Shield Therapeutics compare to Bioventix?

Is BVXP or STX more profitable?

Does the media prefer BVXP or STX?

Which has more risk & volatility, BVXP or STX?

Do analysts prefer BVXP or STX?

Which has higher valuation and earnings, BVXP or STX?

Do institutionals & insiders have more ownership in BVXP or STX?

Summary

How does Shield Therapeutics compare to Venture Life Group?

Which has more risk & volatility, STX or VLG?

Which has higher earnings and valuation, STX or VLG?

Do institutionals & insiders have more ownership in STX or VLG?

Does the media prefer STX or VLG?

Is STX or VLG more profitable?

Do analysts prefer STX or VLG?

Summary

How does Shield Therapeutics compare to Open Orphan?

Does the media prefer STX or ORPH?

Is STX or ORPH more profitable?

Do analysts rate STX or ORPH?

Which has stronger earnings & valuation, STX or ORPH?

Do insiders and institutionals have more ownership in STX or ORPH?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Does the media refer more to EAH or STX?

Is EAH or STX more profitable?

Which has more volatility and risk, EAH or STX?

Do institutionals and insiders believe in EAH or STX?

Which has higher earnings and valuation, EAH or STX?

Do analysts prefer EAH or STX?

Summary

How does Shield Therapeutics compare to Marks Electrical Group?

Does the media prefer STX or MRK?

Which has more volatility and risk, STX or MRK?

Is STX or MRK more profitable?

Do analysts rate STX or MRK?

Which has better valuation & earnings, STX or MRK?

Do institutionals & insiders hold more shares of STX or MRK?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools